ACC CardiaCast

This episode is part of ACC's ongoing effort to advance understanding of inflammation and its role in cardiovascular risk assessment. Drs. Antonio Abbate and Brittany Weber discuss the clinical relevance of high-sensitivity C-reactive protein (hs-CRP), including what it measures, which patients should be considered for testing, and how results can help refine cardiovascular risk discussions beyond traditional risk factors. Through a practical, case-based conversation, they explore how hs-CRP can be incorporated into screening, prevention, and management strategies for patients with or at risk for cardiovascular disease. This podcast is part of the ACC's hs-CRP educational initiative, supported by Novo Nordisk. The program provides educational resources to help clinicians interpret inflammatory risk and apply hs-CRP findings to cardiovascular risk assessment, screening, and management decisions. Click here to learn more: https://learn.acc.org/Page/learnHSCRP   

This episode is part of ACC's ongoing initiative on Implementing the 2026 Dyslipidemia Guidelines. Join Drs. Pam Morris and Roger Blumenthal as they explore updates to the Dyslipidemia Guidelines, the patient populations who benefit most, and how to make sense of all of this new information. They provide a practical, evidence‑based discussion designed to support better decision‑making in everyday care.  This podcast is part of the ACC's Implementing the 2026 Dyslipidemia Guidelines: From Risk Stratification to Personalized Treatment online course, supported by Merck & Co. and Eli Lilly and Company. Visit the online course to access additional educational activities on this topic.

This episode is part of ACC's ongoing initiative to review aortic stenosis care and its approach to screening and diagnosis. Drs. Wayne Batchelor and Sammy Elmariah review the barriers to aortic stenosis diagnosis. The conversation highlights symptom variability, sex-based and demographic differences, and screening gaps in the real-world practice.    This podcast is part of the ACC's Transforming Aortic Stenosis Care: An Optimal Approach to Screening & Diagnosis initiative, supported by an educational grant from Edwards Lifesciences.  

This episode is part of ACC's ongoing initiative on implementing the 2026 Dyslipidemia guidelines. Join Drs. Samuel Kim and Romit Bhattacharya as they review new therapeutic developments from the guidelines during this discussion on the intersections of dyslipidemia and cardiometabolic syndrome management.   This podcast is part of the ACC's Implementing the 2026 Dyslipidemia Guidelines: From Risk Stratification to Personalized Treatment initiative, supported by Merck & Co, and Eli Lilly and Company. 

This episode is part of ACC's ongoing initiative to recognize the risks and tackle management of hypertriglyceridemia (HTG) and severe hypertriglyceridemia (sHTG). Drs. Michael Miller and Archna Bajaj discuss the importance of correctly diagnosing sHTG, recognizing familial chylomicronemia syndrome (FCS), and following guideline‑based testing sequences.  This podcast is part of the ACC's Hypertriglyceridemia and Cardiovascular Health: Recognizing Risks and Tackling Management initiative, supported by Ionis Pharmaceuticals. 

In this CardiaCast episode, Kevin M. Alexander, MD is joined by Sarah Cuddy, MBBCh, to discuss the latest clinical data for investigational therapies and available treatments for transthyretin amyloid cardiomyopathy (ATTR-CM), as well as the potential implications of these findings on clinical practice and future clinical studies. First, they will explore results from CARDIO-TTRansform, the phase 3 trial of eplontersen in ATTR-CM, followed by the results from REVEAL, the phase 3 trial using radiotracer I-124 evuzamitide to detect cardiac amyloidosis. Next, they will discuss findings from ATTRibute-CM and its open-label extension on the survival benefits of acoramidis in variant ATTR-CM (ATTRv-CM) over 54 months. Lastly, they will cover recently published studies describing the extracardiac effects of available therapies for ATTR-CM, specifically those describing the effects of acoramidis on kidney function and the effects of vutrisiran on gastrointestinal events.   This activity is supported by an educational grant from BridgeBio and developed by Med-IQ in collaboration with the American College of Cardiology.                             

This episode of CardiaCast will feature a discussion on risk assessment and genetics in the prevention of cardiovascular disease.   This podcast is supported by Esperion, Merck, and Novartis.

This episode of CardiaCast will feature a discussion on risk assessment and the treatment of hypertriglyceridemia.   This podcast is supported by Esperion, Merck, and Novartis. 

In this final episode of the Increasing Role of UACR in Cardiovascular Care series, Drs. Ankeet Bhatt and Brendan Neuen will break down why UACR screening is one of the most powerful yet underused tools for identifying early cardiovascular risk. Together, they examine the latest evidence on therapies and lifestyle strategies that reduce albuminuria, discuss their impact on kidney and cardiovascular risk, and highlight practical considerations for integrating these approaches into everyday clinical care. This podcast is supported by a grant from Boehringer Ingelheim. Visit the course page to learn more about the role of UACR in Cardiovascular Care. 

The second episode of the Increasing Role of UACR in Cardiovascular Care series focuses on the most recent evidence-based guidelines for elevated UACR and related cardiovascular (CV) conditions. Dr. Ankeet Bhatt interviews Dr. Nihar Desai on key terminology for albuminuria and discuss CV conditions associated with UACR as a biomarker.   This podcast is supported by a grant from Boehringer Ingelheim. Visit the course page to learn more about the role of UACR in Cardiovascular Care.